Cognition Therapeutics to present proteomic biomarker analyses from CT1812

Cognition Therapeutics will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE and Phase 1b SPARC studies with mild-to-moderate Alzheimer’s disease who were treated with either CT1812 or placebo. Results of this analysis identified biomarkers of CT1812 activity that replicated across these two independent studies and patient cohorts. These findings inform our understanding of the impact of CT1812 treatment on the network of biologic pathways associated with Alzheimer’s disease progression. A detailed poster presentation will be made at the upcoming AD/PD 2023: the International Conference on Alzheimer’s & Parkinson’s Diseases being held in Gothenburg, Sweden from March 28 to April 1, 2023. In addition, Lisa Ricciardi, CEO of Cognition Therapeutics will be participating in a panel hosted by the Alzheimer’s Drug Discovery Foundation. The panel, "Emerging Solutions: Novel Approaches to Alzheimer’s Disease" will take place in the Industry Symposium, "Building the Future: Novel Approaches and Innovations in Alzheimer’s Research" being held on March 29, 2023 at 11:40am local time. The panelists will discuss the need for multiple novel approaches to address neurodegenerative diseases with an emphasis on the value of rigorous and biomarker-driven clinical trials to help implement this multipronged approach.